Navigation Links
CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
Date:3/1/2012

BRUSSELS, March 1, 2012 /PRNewswire/ -- CSL Behring is the recipient of a 2012 EURORDIS Award for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions. The global biotherapeutics company, which specializes in plasma-derived and recombinant therapies used to treat congenital bleeding disorders, immune deficiencies, hereditary angioedema and inherited respiratory disease, is a subsidiary of CSL Limited (ASX:CSL).

(Logo:  http://photos.prnewswire.com/prnh/20100914/PH63692LOGO )

One of the primary criteria for the award is a demonstrated commitment to providing access to therapies for people with rare diseases. The award was presented yesterday at the first EURORDIS Gala Dinner in the Hotel Le Plaza. "Solidarity," the theme of 2012 Rare Disease Day, focuses on the importance and the need for collaboration in the field of rare diseases.

"CSL Behring is honored and delighted to receive a 2012 EURORDIS Award," said Senior Vice President of Public Affairs Dennis Jackman. "This award is a reflection of our commitment to providing safe and effective therapies to improve the lives of patients with rare and serious medical conditions.  CSL Behring's commitment is further demonstrated in the company's growing investment in research and development, which has added to an extensive rare disease product portfolio, and in advanced manufacturing facilities and patient support."

CSL Behring received the National Organization for Rare Disorders 2011 Corporate Award for new treatments for rare diseases brought to market in the U.S.

About EURORDIS

EURORDIS is a non-governmental, patient-driven alliance of patient organisations and individuals active in the field of rare diseases, dedicated to improving the quality of life of all people living with rare diseases in Europe.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com or view CSL Limited's Corporate Responsibility Report.

Contact:
Chris Florentz
Manager, Corporate Communications
610-878-4316
Christopher.Florentz@cslbehring.com


'/>"/>
SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
2. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
3. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
4. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
5. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
6. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
7. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
8. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
9. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
10. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
11. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 18, 2017 The drug ... billion by 2021 from USD 1,179.20 billion in 2016, ... Increasing prevalence of chronic diseases, increasing demand for ... factors driving the growth of this market. Whereas, self-administration ... generic drugs offer significant growth opportunities for players operating ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 /PRNewswire/ ... Research, titled, "Breast Imaging Technologies Market by Type: Global Opportunity ... imaging technologies market size was valued at $2,544 million in ... growing at a CAGR of 8.4% from 2016 to 2022. ... together accounted for over three-fourths market share in ...
(Date:1/18/2017)... Jan. 18, 2017   Regenicin, Inc. (OTC ... specializing in the development and commercialization of regenerative cell ... organs, recently reported the Company,s operating results for 2016 ... As the Company described in its recent 10-K ... of substantial accomplishments. The Company,s contract laboratory completed its ...
Breaking Medicine Technology:
(Date:1/19/2017)... Atlanta, Georgia (PRWEB) , ... January 19, 2017 ... ... Reconstructive Surgeons hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of ... latest advancements in breast surgery. Covering topics from cosmetic breast augmentation ...
(Date:1/18/2017)... , ... January 18, 2017 , ... A recent video ... a global discussion about the benefits of fidgeting to relieve stress and anxiety. ... Daniel. Their Think Ink Pen had just completed a successful Kickstarter campaign raising ...
(Date:1/18/2017)... LAUDERDALE, FL (PRWEB) , ... January 18, 2017 ... ... how to manage it from the number one doctor-recommended OTC antiperspirant, Certain Dri. ... and often go untreated. , Certain Dri created this infographic to explain the ...
(Date:1/18/2017)... NJ (PRWEB) , ... January ... ... the specialty pharmacy industry’s leading journal and most-read publication among specialty pharmacists ... University Medical Center through its Strategic Alliance Partnership (SAP) program, announced Brian ...
(Date:1/18/2017)... ... 18, 2017 , ... PrideStaff, a national, franchised staffing ... Paula Turner Pizarro, was recently featured on Fox Business Network's Worldwide Business with ... business leaders from across the globe, provides viewers an opportunity to find solutions ...
Breaking Medicine News(10 mins):